Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Treatment-free remission in patients with chronic myeloid leukemia following the second discontinuation of tyrosine kinase inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

WLWeiming Li

Discussion

Loading...

Member takes

Overview

Retrospective study shows 33.3% of patients reinitiate TKI after MRec, indicating TFR2 is feasible for chronic myeloid leukemia.

Key Points

  • This research aims to evaluate the feasibility of a second discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients.
  • Conducted a retrospective study across 3 institutions.
  • Included 39 patients after they underwent second TKI discontinuation.
  • Patients had achieved MR4.0 for at least 2 years before the first discontinuation.
  • 33.3% of patients had to reinitiate TKI therapy due to molecular relapse after the second discontinuation.
  • Median time to molecular relapse after first discontinuation was 5 months.
  • Majority regained deep molecular response within 6 months after TKI stop.

Cite This Study

Weiming Li (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbe9https://doi.org/10.1182/blood-2025-7302
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study2026
  2. 2Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response2025
  3. 3Molecular remission after tyrosine kinase inhibitor cessation in chronic myeloid leukemia (CML): A systematic review and meta-analysis.2026
  4. 4Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia2026
  5. 5Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?2021 · 20 citations